2022 Fundraising is Here – Are you?

6 Jan

By Rory McCann, Marketing Manager & Conference Producer, LSN

Only a few days into the new year and already one of the biggest fundraising events of the year is starting. Digital RESI JPM, January 11-13 partnering is open and vibrant with hundreds of attendees taking advantage of the opportunities available to fundraising entrepreneurs in 2022. There is still time to sign up for early-stage companies seeking capital, licensing, and strategic partnerships, but even more importantly is the yearlong ecosystem of partnering that companies at all stops along their early-stage journey can take advantage of.

If 2022 is your year to kick your fundraising into high gear, check out the Digital RESI JPM agenda, as well as the plethora of events and services available to help you meet your goals and be successful in the new year.

  Tuesday (1/11) Wednesday (1/12) Thursday (1/13)
10AM EST Innovator’s Pitch Challenge #1 Devices & Diagnostics Family Offices Panel Innovator’s Pitch Challenge #8 Longevity-Devices & Digital Health
Innovator’s Pitch Challenge #5 Oncology Therapeutics & AI Drug Discovery Applications
11AM EST Medical Devices Investor Panel Defining and Funding Age-Tech Innovations Panel Diagnostics Investor Panel
12PM EST Negotiating Term Sheets Licensing in Life Sciences How to Evaluate Your Banking Partner Workshop
1PM EST Innovator’s Pitch Challenge #2 Therapeutics Innovator’s Pitch Challenge #6 Diagnostics & Digital Health Innovator’s Pitch Challenge #9 Devices and R&D Services
 Fundraising Challenges and Highlights of First-Time Founders & CEOs
2PM EST The Regulatory Pathway for AI in Healthcare Panel Digital Health Investor Panel Emerging Products and Technologies for Aging at Home Panel
3PM EST Big Pharma Panel The Early Stage Pivot Panel Corporate VC Panel
Innovator’s Pitch Challenge #3 Oncology Diagnostics Innovator’s Pitch Challenge #10 Medical Devices
4PM EST Tales from the Road: Age-Tech Innovators on their Fundraising Journey Tales from the Road: Biotech and MedTech Innovators on their Fundraising Journey Tales from the Road: AI Innovators on their Fundraising Journey
5PM EST Innovator’s Pitch Challenge #4 AI-Devices & Digital Health Innovator’s Pitch Challenge #7 Therapeutics Innovator’s Pitch Challenge #11 Oncology Therapeutics
Longevity Investors Share Their Investment Thesis Longevity Entrepreneurs Discuss Their New Products

Digital RESI JPM 2022 IPC Finalists

6 Jan

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Happy New Year! Life Science Nation (LSN) is excited to kick off 2022 with Digital RESI JPM next week. A record number of early-stage life science and healthcare companies applied to participate in the Innovator’s Pitch Challenge (IPC) at the upcoming RESI.

Our 54 finalist companies will have a dedicated webpage that includes the company’s key marketing collateral including a short pitch video, available for viewing to all RESI attendees. Most importantly, these companies have been assigned to a 1-hour live Q&A session based on sector/technology, interacting with investors and strategic partners who will ask them targeted questions and provide feedback on their pitches.

We are delighted to feature companies across a wide variety of sectors, including therapeutics, devices, diagnostics, and digital health. See the participating companies below:

Digital RESI JPM 2022 IPC Finalists

Investors at Next Week’s Digital RESI JPM

6 Jan

By Joey Wong, Investor Research Analyst, LSN

Life Science Nation (LSN)’s first and largest event of the year, Digital RESI JPM 2022, is coming up in less than a week. With most of the major events happening around JPM going virtual, LSN has been overwhelmed by the number of registration requests that we have been receiving, as we do our best to ensure that every investor is a direct, active investor who looks at the early-stage life science and healthcare space. With 300+ investors confirmed to attend, including large pharma/medtech, family offices, corporate venture capitals funds, and more, this digital conference is a great opportunity to kick off your fundraising campaign and start a dialog with potential investors and strategic partners in 2022. Register now to meet with these investors:

CI01062022

Hot Investor Mandate: USA Firm With Several Billion AUM Seeks Global Healthcare Opportunities, With Strong Interests in Nucleic Acid-Based Therapeutics and Life Science Tools

6 Jan

A multi-billion AUM firm based in the USA is known for investing in technologies that change paradigms. The firm is currently investing out of a $1 billion venture fund for later stage investments and a $400 million for seed-stage investments. The firm has invested across a multitude of industries, including healthcare. Within healthcare, the firm is agnostic, choosing to select companies based on their potential impact. The firm will invest globally and generally prefer Seed and Series A opportunities for new investments.

While the firm is agnostic to sector and indication, the firm does have several areas of particularly high interest. Currently, the firm is interested in nucleic acid-based technologies and therapeutics, manufacturing and automation tools, and discovery tools. While the firm is open to any indication, the firm does prefer to invest in less crowded disease areas.

The firm places a strong emphasis on the team when investing.
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Corporate Venture Arm Strategically Invests in Devices and Digital Health Companies Dedicated to Elderly Care and Improving Quality of Life

6 Jan

The corporate venture arm of a senior living community invests strategically in companies that can enhance their services or the elderly population quality of life in general, including in healthcare. Within healthcare, the firm is willing to invest in digital health, medical devices and diagnostic/monitoring technologies, but will not invest in therapeutics. The firm generally invests in seed to series A, and will occasionally act as a company builder, co-founding a company around a promising technology. In an initial investment, the firm will generally invest no more than $.5M, but has the ability to invest in follow-on rounds. As a strategic investor, in addition to capital, the firm can employ their facilities for pilot programs, and will occasionally do so before investing. The firm is primarily interested in Israeli companies, but will invest globally.

The firm invests in multiple sectors related to the elderly population quality of life. These technologies can include medical devices, diagnostics and digital health technologies. Examples include chronic disease management software or monitoring devices.

The firm invests in multiple sectors related to the elderly population quality of life. These technologies can include medical devices, diagnostics and digital health technologies. Examples include chronic disease management software or monitoring devices.
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Corporate VC of Large, Global Corporation With a Thriving Healthcare Business Interested in Therapeutics, Digital Therapeutics, Medical Devices, and More 

6 Jan

The holding company of a large corporation is dedicated to fostering innovation across by investing in and partnering with strategic startups. The corporate venture capital arm is open to global opportunities and is geography and stage agnostic, but has specific preferences depending on the technology sector.

Healthcare/Medical is one of the major focus areas of the firm. The corporate venture capital arm is interested therapeutics solutions such as solutions beyond the pill (digital therapeutics) and around the pill (delivery systems etc). Therapeutics areas of interest are CNS, Autoimmune diseases, metabolic diseases, regenerative medicine, Aging related solutions and Vaccines. The corporate venture capital arm is also interested in diagnostics solutions based on genomics, metagenomics, metabolomics, healthcare ICT (biosensors etc), and medical big data. Furthermore, medical devices for wound care, bone cement and hospital related infection treatment is also is an area of interest and is open to all classes of medical devices including 510k and PMA.

The corporate venture capital arm has a close, collaborative relationship with other business branches within the corporation, and can also present opportunities to the pharma branch, CRO, CDMO branches as appropriate.

The firm is a flexible investor and does not require companies to have a Japan-centric angle. For medical device & digital therapeutics opportunities, the group does prefer technologies with strong promise in the US market. The venture group has a close relationship with all other business operations within the corporation and can actively support companies by leveraging these relationships.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Transatlantic Advisory and Investment Firm Seeks Opportunities in Therapeutics, Devices, Diagnostics, and Digital Health, Bringing Together US and Europe-Based Teams

6 Jan

A transatlantic advisory and investment firm based in USA and Europe advises and invests exclusively in the life science space. The firm brings together early-stage US and EU based life science companies to bridge the Atlantic, gain scale and de-risk. It helps negotiate collaboration agreements and a road map towards a merger. The firm investment arm will invest $2-6M in the form of equity or convertible notes, for the most promising newly merged entities, by turning to a group of pledge investors. In the future, the firm is looking to raise a $100M transatlantic fund comprised of US and EU based sister funds that would invest jointly in the merged entities.

The firm seeks companies in all four life science sectors including therapeutics, medical devices, diagnostics, and digital health and is agnostic to both subsector and indication. The firm is open to preclinical and pre-prototype companies and all three classes of medical devices.

The firm’s whole focus is to bring together US and European teams, and starts the process by contacting companies looking to cross the Atlantic and establish a presence via a partnership. The firm looks for companies with a solid core team and the bandwidth to negotiate and build a transatlantic partnership that may evolve into a full-scale merger. The firm looks for companies in early stage, but not necessarily startups, since the core team is important. The firm also provides integration services to help the teams complement each other and work well together, a factor critical to the success of the merged entity. After engineering the merger, the firm will seek to take advantage of the significantly higher valuation to lead a new funding round. In these cases, the firm would seek a board seat.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →